Latest Headlines

Latest Headlines

AdvaMed: China's push for hospitals to buy domestic devices all talk, no action

AdvaMed's executive vice president of global strategy and analysis told FierceMedicalDevices  that China has not implemented its much-ballyhooed policy of using more domestic devices at its hospitals at the expense of foreign imports.

China's 3SBio buys Sirton for play in injectables

China-based biotechnology company 3SBio bought the entire share capital of Italy-based pharmaceutical contract manufacturing company Sirton Pharmaceuticals from First Shanghai, the company said on Jan. 26.

Pharmaceuticals and biotech a backdrop to China-Taiwan economic talks

Pharmaceuticals and biotechnology per se are not officially on the agenda, but both industries could be affected by the semi-annual meeting of the Cross-strait Economic Cooperation Committee set for Jan. 29 in Taipei. Taiwan biotechs meet a week later.

GSK refutes reports the ax is about to fall on jobs in China

GlaxoSmithKline is struggling to grow sales post-China bribery scandal, cutting jobs in the U.S. while focusing on a long-term overhaul to manufacturing and R&D to chart some upward momentum. The company was said to be exploring job cuts in China to deliver a much-needed boost to its bottom line, but GSK is refuting those reports, potentially taking a different route to get business back on track.

China announces landmark medical device GSP rules

SINGAPORE-- China's FDA has issued the country's first GSP (Good Supply Practices) rules that will cover 1, 2 and 3 medical device distributors, as it moves to harmonize practices followed elsewhere in the world and rein in service providers of medical devices that may not have detailed technical expertise.

China's Innovent banks $100M to cash in on the biosimilar boom

Innovent Biologics has raised $100 million in venture cash in hopes of becoming the premier maker of biotech drugs in its native China, advancing a pipeline of biosimilars and proprietary treatments.

J&J faces sales, currency headwinds abroad in 2015

Johnson & Johnson was strongly hit by weaker currencies across Asia in the fourth quarter with the company struggling to hedge risk, indicating to executives that further impacts to the bottom line in these fast-growing markets are expected in 2015.

Alibaba's Jack Ma plows big bucks into Baiyunshan to boost China online drug sales

Guangzhou Baiyunshan Pharmaceutical Co. ($600332) plans to raise RMB 10 billion ($1.6 billion) to fund its research and development programs and expand product distribution is banking on support from Yunfeng, a private equity firm co-founded by Jack Ma, chairman and founder of the Alibaba Group ($BABA).

China bans import of U.S. poultry products on avian flu fear

This week, China joined a growing list of countries banning the import of U.S. poultry products following reports of the discovery of a highly contagious strain of avian influenza in three West Coast states.

China FDA plans to lift ban on online drug sales

The China Food and Drug Administration plans to allow online sales of prescription drugs as early as this month, opening up the market to existing online e-commerce platform operators like Alibaba.com and JD.com.